UniQure submits Huntington's gene therapy to the FDA for review

UniQure has submitted its Huntington's disease gene therapy to the US Food and Drug Administration (FDA), according to reporting by STAT News. The submission, if accepted for review, would make the therapy one of the first gene therapy candidates for Huntington's disease to enter formal US regulatory evaluation.

Huntington's disease is an autosomal dominant neurodegenerative condition caused by an expanded CAG trinucleotide repeat in the HTT gene on chromosome 4p16.3. Longer repeat lengths are associated with earlier disease onset. There are currently no approved therapies that slow disease progression; treatment remains symptomatic.

UniQure's programme uses an adeno-associated virus (AAV) vector to deliver a microRNA targeting the mutant HTT transcript, aiming to reduce the production of the toxic huntingtin protein. Earlier clinical data from the programme have been reported at conference meetings, though peer-reviewed phase 3 results have not yet been published at the time of this summary.

Full details of the regulatory submission — including the dataset package presented to the FDA — have not been publicly disclosed. The FDA will determine whether the application is accepted for priority review or standard review. Regulatory decisions typically follow submission by several months to a year. Researchers following the broader landscape of HTT-lowering approaches — including antisense oligonucleotides and small-molecule strategies — will watch this submission closely.